Plain-English translation of NCT06940830 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia A research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a long-term study that follows people with hemophilia A who are taking as a preventive treatment. Researchers want to understand how well this medication protects joint health in real-world conditions—meaning in everyday life, not just in controlled lab settings. The study will collect information about bleeding episodes, joint health, and how people feel over 2–3 years.
Hemophilia A can cause bleeding into joints, which over time leads to joint damage and arthritis. Doctors want to know whether this preventive medication truly helps protect joints from this long-term damage when people use it in their daily lives.
You likely qualify if…
You likely don't qualify if…
You will come to the hospital or clinic about once per year for 2–3 years. At each visit, doctors will examine your joints using a physical exam, and some participants will also have ultrasound scans of their joints. You'll complete questionnaires about how you're feeling and answer questions about any bleeding episodes. You'll also keep a simple paper diary at home to record any bleeding that happens between visits. Your medical records from the year before you started the medication will be reviewed, and your health will be monitored throughout the study while you continue taking the preventive treatment.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
Croatia
Czechia
France